Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2015

View Archived Issues

Nucleic acid antibody prophylaxis as an antiviral immunotherapy for dengue

FDA OOPD awards grant to support development of ADXS-HPV in throat cancer

PeptiDream and Sanofi establish peptide discovery collaboration

RaQualia selects RQ-00433412 for preclinical development in cancer cachexia

STAT2 regulates mitochondrial fission

Baxalta files for U.S. approval of 20% immunoglobulin subcutaneous

XenoPort reports phase II study data for XP-23829

P2X7R antagonist reduces neuronal death in epilepsy model

Amicus Therapeutics to submit NDA for migalastat for Fabry disease

Teijin Pharma and Amgen report ROR-gamma antagonists

BARDA funding awarded to Crucell Holland to accelerate Ebola vaccine program

Laboratoire Biodim discloses dltA inhibitors

Glenmark Pharmaceuticals' GBR-1302 to enter phase I trials

Ono Pharmaceutical describes EP2 agonists

Jiangsu Ascentage Biomed Development reports ALK inhibitors

Andexanet alfa achieves rapid and sustained reversal of rivaroxaban in phase III trial

Sichuan Haisco Pharmaceutical reports phosphoramidate antivirals

Mylan initiates offer for Perrigo shares, Perrigo tells shareholders to wait

RepliCel starts phase I trial of autologous fibroblast therapy RCS-01

AZTherapies initiates phase III study of ALZT-OP1 for early Alzheimer's disease

Seegene and BD Life Sciences collaborate to develop multiplex molecular diagnostic assays

Bionomics reports data from phase I trial of BNC-210 for anxiety and depression

Depomed urges shareholders to reject Horizon Pharma's unsolicited exchange offer

Hemostemix signs strategic alliance agreement with Hemostemix Asia for ACP-01

Cotranstplantation of islets and dental pulp stem cells improves survival in diabetic mice

ALCAM mediates late kidney complications of diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...